Who
Karin Eastham
Director
Company insider
Files Form 4 as: Director, Veracyte; Director, Personalis; Director, Geron; Director, Nektar Therapeutics; Director, Illumina; Director, Trius Therapeutics; Director, Amylin Pharmaceuticals; Director, Genoptix.
In numbers
- Trades disclosed
- 368
- Buys
- 0
- Sells
- 39
- Bought
- $0
- Sold
- $170.0M
- Companies
- 10
- Companies where not an officer
- 10
- First trade
- 7 Oct 2005
- Last trade
- 18 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 22 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $169K3,200 at $52.78 | filing |
| 18 Jun 2026filed 22 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $28K529 at $53.55 | filing |
| 18 Jun 2026filed 22 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $169K3,200 at $52.78 | filing |
| 18 Jun 2026filed 22 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $28K529 at $53.55 | filing |
| 11 Jun 2026filed 15 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —5,272 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —5,272 at $0.00 | filing |
| 12 May 2026filed 11 Jun 2026 | PSNL PersonalisDiagnostics & Labs | SEC FORM 4 Code A | —6,250 at $0.00 | filing |
| 12 May 2026filed 11 Jun 2026 | PSNL PersonalisDiagnostics & Labs | SEC FORM 4 Code A | —6,250 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | PSNL PersonalisDiagnostics & Labs | SEC FORM 4 Code A | —6,250 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | PSNL Personalisoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | PSNL Personalisoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | PSNL PersonalisDiagnostics & Labs | SEC FORM 4 Code A | —6,250 at $0.00 | filing |
| 5 Dec 2025filed 8 Dec 2025 | VCYT Veracyteoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 5 Dec 2025filed 8 Dec 2025 | VCYT Veracyteoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 5 Dec 2025filed 8 Dec 2025 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code M | $79K10,000 at $7.94 | filing |
| 5 Dec 2025filed 8 Dec 2025 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code M | $76K10,000 at $7.60 | filing |
| 5 Dec 2025filed 8 Dec 2025 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $285K6,392 at $44.52 | filing |
| 5 Dec 2025filed 8 Dec 2025 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $587K12,808 at $45.84 | filing |
| 5 Dec 2025filed 8 Dec 2025 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $37K800 at $46.59 | filing |
| 5 Nov 2025filed 7 Nov 2025 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $387K9,674 at $40.02 | filing |
News
No headline names them, or the companies they trade most, lately.